Your browser doesn't support javascript.
loading
CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy.
Zafar, Sadia; Sorsa, Suvi; Siurala, Mikko; Hemminki, Otto; Havunen, Riikka; Cervera-Carrascon, Victor; Santos, João Manuel; Wang, Hongjie; Lieber, Andre; De Gruijl, Tanja; Kanerva, Anna; Hemminki, Akseli.
Affiliation
  • Zafar S; Cancer Gene Therapy Group, University of Helsinki, Helsinki, Finland.
  • Sorsa S; Cancer Gene Therapy Group, University of Helsinki, Helsinki, Finland.
  • Siurala M; TILT Biotherapeutics Ltd, Helsinki, Finland.
  • Hemminki O; Cancer Gene Therapy Group, University of Helsinki, Helsinki, Finland.
  • Havunen R; TILT Biotherapeutics Ltd, Helsinki, Finland.
  • Cervera-Carrascon V; Cancer Gene Therapy Group, University of Helsinki, Helsinki, Finland.
  • Santos JM; Division of Urology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
  • Wang H; Cancer Gene Therapy Group, University of Helsinki, Helsinki, Finland.
  • Lieber A; TILT Biotherapeutics Ltd, Helsinki, Finland.
  • De Gruijl T; Cancer Gene Therapy Group, University of Helsinki, Helsinki, Finland.
  • Kanerva A; TILT Biotherapeutics Ltd, Helsinki, Finland.
  • Hemminki A; Cancer Gene Therapy Group, University of Helsinki, Helsinki, Finland.
Oncoimmunology ; 7(10): e1490856, 2018.
Article in En | MEDLINE | ID: mdl-30386680
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Oncoimmunology Year: 2018 Document type: Article Affiliation country: Finland
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Oncoimmunology Year: 2018 Document type: Article Affiliation country: Finland